Dublin, February 08, 2021 (GLOBE NEWSWIRE) – Added to the report “Breast Cancer Screening Market, Patients, Global Mortality Prediction by Type of Test (Pap Smear, HPV DNA, VIA), 19 Country Studies” ResearchAndMarkets.com’s offering.
The Global Cervical Cancer Screening Market is expected to reach USD 16.5 Billion by 2026.
Globally, cervical cancer is the most common cancer in women. Breast cancer is most commonly diagnosed in women between the ages of 35 and 44 with an average age of diagnosis at 50. In 2019, approximately 283.15 million women were diagnosed with breast cancer worldwide , and approximately 311,000 women died from the disease in 2018. Breast cancer is the fourth most common cancer in women and seventh in terms of overall cancer incidence.
There are three types of screening to identify breast cancer, namely Pap Smear Tests, Human Papillomavirus (HPV) Tests and Visual Acetic Acid (VIA) Tests. These screens are a key feature that is expected to increase the number of screening tests over the expected period. An effective primary procedure (HPV vaccine) (testing and treating predictive lesions) prevents most breast cancer cases.
This report provides analysis & forecast of 19 countries breast cancer market with numbers of screening & mortality. In the United States, the medical community has taken great strides in the prevention and control of breast cancer. The reasons influencing world market leadership are the presence of technological advances in new inspection equipment, inspection methods, favorable government policies related to reimbursement and screening methods. which is expected to have a positive impact on the market. Breast cancer is one of the leading causes of female cancer deaths in low- and middle-income countries.
COVID-19 affects the global breast cancer screening industry
Breast cancer screening declined to rare numbers due to pandemic coronavirus. Most non-emergency breast cancer meetings were postponed after COVID-19. However, things have started to move in the last two quarters, but will not return to pre-COVID numbers this year. How prevention measures should be implemented during efforts to provide breast cancer screening in accordance with health authorities’ guidance. Read the full analysis on how COVID-19 affected the breast cancer screening market and its future?
Breast cancer mortality
In this section the number of deaths from breast cancer in the 19 countries from 2014 to 2020 was captured. The report gives full insights of Market, Screened Population & Mortality of 19 countries, which provides a general view of the analysis of countries around the world on Global Cervical Cancer Screening Industry.
Market dynamics
Growth drivers
- Introduce a low cost VIA test
- Countries Offer VIA Testing through National Programs
- Countries offering VIA Testing through Pilot Programs
- High rate of patients with HPV infection worldwide
- Rising number of breast cancers in the United Kingdom
- A rising worldwide incident of teenage sexual issues
Challenges
- Lack of adequate Healthcare Infrastructure
- Introduce HPV vaccination programs worldwide
Key topics covered:
1. Introduction
2. Research Methodology
3. Executive Minutes
4. Global Cervical Cancer Test Number (Screening)
4.1 Asia
4.2 Europe
4.3 North America
4.4 Rest of the world
5. Global Cervical Cancer Testing Market (Screening)
5.1 Pap Smear Test (Screening)
5.2 HPV DNA Testing (Screening)
6. By Region – Global Cervical Cancer Testing Market Study (Screening)
6.1 Asia
6.2 Europe
6.3 North America
6.4 Rest of the world
7. Population Share – Global Breast Cancer Test (Screening)
7.1 By area
7.2 By country
8. Market share – Global breast cancer test (screening)
8.1 Section – Breast Cancer Test (Screening)
8.2 Countries – Breast Cancer Test (Screening)
8.3 Countries – Smear Pap Test (Screening)
8.4 Countries – HPV DNA Testing (Screening)
8.5 Countries – VIA Test (Screening)
Covered countries
- Canada
- China
- France
- Germany
- India
- Indonesia
- Italy
- Japan
- Korea
- Malaysia
- Netherlands
- Norway
- Singapore
- Spain
- Sweden
- Switzerland
- Thailand
- United Kingdom
- United States
For more information about this report, visit https://www.researchandmarkets.com/r/3v61et
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900